血清缓激肽与前列腺癌的相关性研究

目的 探讨血清缓激肽在前列腺癌的诊断及鉴别诊断中的临床应用价值.方法 收集68例前列腺癌患者和32例前列腺增生患者,以同期体检的健康男性32例为对照组,收集其血清,酶联免疫吸附试验(enzymelinked immuno sorbent assay,ELISA)法检测血清中的缓激肽水平,比较各组血清缓激肽水平的差异以及前列腺癌患者在不同年龄、临床分期、病理分期(Gleason评分)、前列腺特异抗原(prostate specific antigen,PSA)水平、肿瘤体积以及骨转移、淋巴结转移、局部侵犯与否状态下血清缓激肽水平的差异.比较血清缓激肽与PSA联合诊断前列腺癌和PSA独立诊断前列腺癌的敏感度差异.结果 前列腺癌组血清缓激肽水平(16.44 ±0.91) μg/L]低于对照组(19.72±1.10) μg/L]和前列腺增生组(20.93±1.80) μg/L],差异均具有统计学意义(均P＜0.05).在肿瘤体积较大的前列腺癌患者血清缓激肽水平较低(P＜0.05),而血清缓激肽水平在年龄、肿瘤临床分期、病理分期(Gleason评分)、PSA水平及骨转移、淋巴结转移、局部侵犯与否方面比较差异均无统计学意义(均P＞0.05).血清缓激肽与PSA联合诊断前列腺癌较单独诊断敏感度提高(P＜0.05).结论 前列腺癌患者血清缓激肽表达水平较低,且与肿瘤体积相关.血清缓激肽与PSA联合诊断前列腺癌敏感度较单独诊断高.

Association of serum bradykinin and prostate cancer

Objective To investigate the clinical application of serum bradykinin in the diagnosis and differential diagnosis of prostate cancer.Methods Sixty-eight eases of prostate cancer and 32 cases of benign prostate hyperplasia (BPH) were enrolled,together with 32 healthy male subjects.Serum samples were collected,and the bradykinin level was detected by enzyme-linked immunesorbent assay (ELISA).The serum levels of bradykinin were compared for each group of patients,and were also compared in prostate cancer patients of different age,clinical stage,pathological stage (Gleason score),prostate specific antigen (PSA) levels,tumor volume,bone metastases status,lymph node metastases status and local invasion level.The sensitivities of prostate cancer diagnosis were compared between bradykinin and PSA combined method and PSA alone.Results The serum bradvkinin level was lower in the prostate cancer group (16.44 ± 0.91) μg/L] than the control group (19.72 ± 1.10) μg/L] and the BPH group (20.93 ± 1.80) μg/L,P ＜0.05].The serum bradykinin level was lower in prostate cancer patients with greater tumor volume (P ＜ 0.05),but not significantly associated with age,clinical stage,pathological stage (Gleason score),PSA levels,bone metastasis,lymph node metastasis,or local invasion (P ＞ 0.05).Serum bradykinin combined with PSA improved the diagnostic sensitivity of prostate cancer compared with PSA alone (P ＜ 0.05).Conclusion Prostate cancer patients have lower serum bradykinin level,which is related with tumor volume.Combination of serum bradykinin and PSA increased the diagnostic sensitivity for prostate cancer compared with the PSA alone method.